Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.
You may also be interested in...
Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients
Given the risks of progressive multifocal leukoencephalopathy, a proposed restriction appears aimed at blunting the potentially unfavorable impact that longer duration of use in the first-line setting would have on natalizumab’s risk/benefit profile.
Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients
Given the risks of progressive multifocal leukoencephalopathy, a proposed restriction appears aimed at blunting the potentially unfavorable impact that longer duration of use in the first-line setting would have on natalizumab’s risk/benefit profile.
Pipelines, Not the Bottom Line, Define 2012 For Investors
More than two dozen biotechs offer 2x returns in 2012, as investors pin their hopes on some hematology oncology and CNS plays. Investors think the party may continue into next year, but perhaps not so giddily.